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Abstract 
Expression of CXCR4 in cancer has been found to correlate with poor prognosis and re-
sistance to chemotherapy. In this study we developed a derivative of the CXCR4 peptide 
antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby 
enable  in  vivo  visualization  of  CXCR4  in  tumors.  T140  was  conjugated  to 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono (N-hydroxysuccinimide ester) 
(DOTA-NHS) to give T140-2D, which contains a DOTA molecule on each of the two lysine 
residues. 
64Cu-T140-2D was evaluated in vitro by migration and binding experiments, and in 
vivo  by  microPET  imaging  and  biodistribution,  in  mice  bearing  CXCR4-positive  and 
CXCR4-negative  tumor  xenografts.  T140-2D  was  labeled  with  copper-64  to  give 
64Cu-T140-2D in a high radiochemical yield of 86 ± 3% (not decay-corrected) and a specific 
activity of 0.28 - 0.30 mCi/µg (10.36 – 11.1 MBq/µg). 
64Cu-T140-2D had antagonistic and 
binding characteristics to CXCR4 that were similar to those of T140. In vivo, 
64Cu-T140-2D 
tended to bind to red blood cells and had to be used in a low specific activity form. In this new 
form 
64Cu-T140-2D enabled specific imaging of CXCR4-positive, but not CXCR4-negative 
tumors. Undesirably, however, 
64Cu-T140-2D also displayed high accumulation in the liver 
and kidneys. In conclusion, 
64Cu-T140-2D was easily labeled and, in its low activity form, 
enabled imaging of CXCR4 in tumors. It had high uptake, however, in metabolic organs. 
Further research with imaging tracers targeting CXCR4 is required. 
Key words: T140 peptide; CXCR4 imaging; PET; copper-64 
Introduction 
CXCR4,  a  member  of  the  chemokine  receptor 
subfamily  of  seven-transmembrane-domain  G- 
protein  coupled  receptors,  is  a  highly  conserved 
chemokine receptor and can be detected on a diverse 
range of cells, including lymphocytes and monocytes, 
mast cells, adult CD34+ bone marrow progenitor cells, 
microglia  and  neurons  [1-6].  CXCR4  and  its  sole 
known human natural ligand, SDF-1/CXCL12, were 
found  to  be  crucial  during  embryonic  growth  and 
development and depletion of either one of them is Theranostics 2011, 1 
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lethal for the embryo [7]. 
CXCR4 functions as an HIV co-receptor for entry 
of T-tropic, but not M-tropic strains of HIV-1 viruses 
into CD4+ T cells [1, 8]. As such, multiple CXCR4 an-
tagonists  have  been  developed,  consisting  of  small 
molecules,  peptides  and  antibodies  [9].  Further  re-
search into the functions of CXCR4 under normal and 
pathologic  conditions  revealed  that  CXCR4  antago-
nists can be used for stem cell mobilization and an-
ti-tumor therapy [9]. 
CXCR4  expression  was  also  found  in  various 
human cancer types, including breast, prostate, lung, 
lymphoma,  multiple  myeloma,  melanoma,  ovarian, 
pancreatic,  neuroblastoma,  esophageal,  colorectal, 
osteosarcoma,  and  renal  cancer  [10-18].  Further  re-
search on the role of CXCR4 in cancer discovered a 
correlation between high levels of CXCR4 expression 
with poor prognosis [19-20], chemotherapy resistance 
[17-18, 21] and development of metastasis in CXCL12 
expressing organs [22-23]. Therefore, CXCR4 became 
an  attractive  target  for  therapy  as  well  as  imaging. 
Development of specific tracers of CXCR4 for positron 
emission tomography (PET), will allow non-invasive 
evaluation  of  the  receptor  levels  in vivo  before  and 
after chemotherapies or future anti-CXCR4 therapies. 
Several CXCR4 ligands have been radiolabeled 
for  PET  and  single  photon  emission  computed  to-
mography  (SPECT)  imaging  [24-29],  and  each  dis-
played  different  advantages  and  disadvantages. 
Nevertheless, an optimal biomarker, in terms of sim-
plicity of synthesis along with selectivity of the tracer, 
has yet to be found. As an example, we and others 
reported that [64Cu]AMD3100 showed extremely high 
specific accumulation in the liver which did not seem 
to  be  CXCR4-dependent,  suggesting  that 
[64Cu]AMD3100  binds  to  another  unknown  target 
receptor [28-29]. We have also developed a radiosyn-
thesis  route  to  label  a  peptide-based  antagonist 
4F-benzoyl-TN14003 (T140, Fig. 1) with the PET iso-
tope  fluorine-18,  without  changing  the  chemical 
structure  of the  peptide  [27]. Although  18F-T140 ac-
cumulated in CXCR4 positive tumors, it also bound to 
red  blood  cells  (RBCs),  and  injection  of  additional 
unlabeled mass of the peptide was required to visu-
alize CXCR4 in vivo [27]. Another downside was the 
long time required for 18F-T140 radiosynthesis and the 
low yield.  
In this paper, we have simplified the synthesis of 
T140-based  tracer  by  conjugation  of 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid  mono  (N-hydroxysuccinimide  ester) 
(DOTA-NHS), and we have labeled it with the longer 
lived  PET  isotope  copper-64  to  give  64Cu-T140-2D 
derivative.  The  tendency  of  64Cu-T140-2D  to  bind 
human CXCR4 receptor and mouse and human RBCs, 
and its ability to be used as a biomarker for imaging 
CXCR4 expression in vivo, were assessed.  
 
 
Figure 1. Schematic structure of T140 and T140-2D. For 
64Cu-labeling, T140-2D was reacted with [
64Cu]Cu(OAc)2 for 20 
min at 40 ºC. 
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Material and methods 
General 
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraace
tic  acid  mono  (N-hydroxysuccinimide  ester) 
(DOTA-NHS)  was  purchased  from  Macrocyclics 
(Dallas, TX). All  other  solvents and chemicals were 
purchased from Sigma–Aldrich (St. Louis, MO). 64Cu 
was  produced  at  the  National  Institutes  of  Health 
(NIH) by the irradiation of a thin layer of 64Ni (Isoflex, 
USA)  electroplated  on  a  solid  gold  internal  target 
plate in a CS-30 cyclotron utilizing the nuclear reac-
tion  64Ni(p,  n)64Cu,  and  separated  from  the  target 
material as [64Cu]CuCl2 by anion chromatography, as 
previously  described  [30].  C18  cartridges  (Waters 
Corporation, Milford, MA) were each activated with 
both 5 mL of EtOH and 10 mL of water. Radio-TLC 
was  performed  on  an  AR-2000  Bioscan  scanner 
(Washington DC), using silica gel plates (LK6DF, 60 
Å,  200  mm,  Whatman)  and  1%  ethylenediaminetet-
raacetic acid (EDTA), 5% NH4OAc in water : methanol 
(1:1) as a developing solvent. T140 peptide was pur-
chased from C.S. Bio Co. (Menlo Park, CA).  
T140  (C97H144FN33O19S2):  observed  2162.48 
[M+3H+], calculated: 2159.52.  
Radioactive samples were counted on a gamma 
counter (1480 Wizard 3, Perkin–Elmer, Boston, MA). 
High  performance  liquid  chromatography  (HPLC) 
was  performed  on  a  system  with  a  variable  wave-
length detector operating at 280 nm and with a radi-
oactivity  detector  with  a  NaI  crystal.  For 
semi-preparative reversed-phase (RP) HPLC, a Hig-
gins preparative C18 column (5 µm, 20 x 250 mm) was 
used. The flow was set at 12 mL/min using a gradient 
system, starting from 95% of solvent A (0.1% TFA in 
water) and 5% of solvent B (0.1% TFA in acetonitrile 
(ACN))  and  increasing  to  35%  solvent  A  and  65% 
solvent B at 35 min. For analytical RP-HPLC, a Vydac 
C4 (214TP5415, 5 µm, 4.6 x 150 mm) column was used. 
The flow was set at 1.5 mL/min with a gradient sys-
tem starting from 100% of solvent A and 0% of solvent 
B and increasing to 70% solvent A and 30% solvent B 
at  30  min.  Mass  spectrometry  analysis  employed  a 
Waters  LC-MS  system  (Waters,  Milford,  MA)  that 
included an Acquity UPLC system coupled to a Wa-
ters Q-Tof Premier high resolution mass spectrome-
ter. An Acquity BEH Shield RP18 column (150 x 2.1 
mm) was employed for chromatography.  
Synthesis of T140-2D 
The  procedure  for  conjugation  of  DOTA-NHS 
with T140 was conducted by dissolving the peptide 
(2-3  mg,  0.92-1.38  µmol)  in  0.2-0.3  mL  dimethylfor-
mamide (DMF). Then, 2.5 eq. of DOTA-NHS in 0.1 mL 
of DMF were added, followed by the addition of 5 eq. 
of diisopropylethylamine. The reaction was mixed at 
4°C overnight. The conjugated peptide was purified 
by  semi-preparative  HPLC.  The  purity  of  T140-2D 
was confirmed by analytical HPLC with a retention 
time  of  13.81  min  (purity  >  99%)  and  identity  con-
firmed  by  LC-MS:  T140-2D  (C129H196FN41O33S2):  ob-
served 2934.54 [M+3H+], calculated: 2931.31. 
64Cu radiolabeling  
[64Cu]CuCl2 was converted to [64Cu]Cu(OAc)2 by 
adding 0.5 mL of 0.4 M ammonium acetate (NH4OAc) 
solution  (pH  =  5.5)  to  20  μL  [64Cu]CuCl2. 
[64Cu]Cu(OAc)2 solution (0.2 mL; 10-12 mCi, 370-444 
MBq) was added into a solution of conjugated peptide 
T140-2D (36 µg) in 0.4 M NH4OAc (pH = 5.5). The 
reaction was stirred for 20 min at 40°C. Complexation 
of 64Cu and the conjugated peptide was monitored by 
radio-TLC (Rf [64Cu]T140-2D = 0.06, Rf [64Cu]Cu2+ = 
0.9). Radio-TLC showed incorporation of greater than 
95%. The reaction vial was then diluted with 10 mL of 
water and loaded onto an activated C18 Sep-Pak car-
tridge. The cartridge was washed with water (10 mL), 
and the desired labeled peptide was eluted with 10 
mM HCl in ethanol (1 mL) into a glass test tube. The 
ethanol was evaporated for 5 min under a stream of 
argon at 40°C and the labeled peptide was then re-
formulated  with  saline.  The  overall  radiochemical 
yield was 86 ± 3% (not decay-corrected, n = 6), calcu-
lated from the start of synthesis to the reformulation 
of the labeled peptide with saline. [64Cu]T140-2D was 
achieved with a specific activity of 0.28 - 0.30 mCi/µg 
(10.36 – 11.1 MBq/µg). Quality control (QC) analysis 
was  performed  on  an  analytical  HPLC  system.  The 
retention  time  of  [64Cu]T140-2D  was  14.02  min. 
64Cu-T140-2D  was  achieved  in  radiochemical  purity 
greater than 99%. 
Cell Culture 
Wild-type Chinese hamster ovarian (CHO) cells 
and  CHO  cells  that  were  stably  transfected  with 
CXCR4 (CHO-CXCR4) were a kind gift from Dr. Da-
vid  McDermott  (NIAID,  NIH,  Bethesda,  MD).  The 
CHO  cells  were  grown  in  F-12K  medium  (ATCC). 
Jurkat  cells  (ATCC)  were  grown  in  Roswell  Park 
Memorial Institute  (RPMI) medium. All cell culture 
media were supplemented with 10% fetal bovine se-
rum, 1 mM sodium pyruvate, 2 mM L-glutamine and 
non-essential amino acids (GIBCO) at 37°C under an 
atmosphere  containing  5%  CO2.  CXCR4  level  ex-
pressed by CHO-CXCR4 cells was evaluated using the 
FlowCellect  kit  (Millipore,  Bedford,  Massachusetts) 
following  the  manufacturer’s  instructions  and  were 
found to be 6.8 x 105 receptors per cell [27]. Theranostics 2011, 1 
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Flow cytometry 
Cells were blocked in HBSS buffer (Hanks' bal-
anced salt solution) supplemented with 2% rat serum 
and 2% mouse serum (Jackson ImmunoResearch labs, 
West Grove, PA) on ice for 10 min, and thereafter cells 
were stained with PE-conjugated anti-human CXCR4 
(R&D,  Minneapolis,  MN).  Cells  from  tumors  were 
also  stained  using  FITC-labeled  anti-mouse  MHC-I 
H-2Dk  (Becton  Dickinson,  San  Jose,  CA).  Flow  data 
were  acquired  using  an  LSR-II  cytometer  (Becton 
Dickinson, San Jose, CA) and analyzed using FlowJo 
(Tree star, Ashland, OR). 
Transwell Migration Assay 
Six  hundred  µL  of  migration  medium  (RPMI 
supplemented with 1% fetal bovine serum) containing 
CXCL12 (PeproTech, Rocky Hill, NJ) at a concentra-
tion of 100 ng/mL were placed into the lower cham-
ber  of  a  Costar  24-well  Transwell  (Corning  Inc., 
Corning,  NY).  Jurkat  cells  (105 in  100  µL  migration 
medium)  were  incubated  alone  with  T140  or  with 
T140-2D at the indicated concentration 15 min before 
they were placed into the upper chamber (pore size 5 
µm). Cells were collected from lower chamber after 3 
h of migration at 37 ºC, and counted by flow cytome-
try  using  counting  beads.  Control  migrations  were 
performed  without  the  chemokine  in  the  lower 
chamber.  
CXCR4 Receptor Binding Assay 
CHO-CXCR4 cells were trypsinized and resus-
pended  in  PBS  containing  50  mM  HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
1 mM CaCl2, 5 mM MgCl2, 0.5% (w/v) BSA and 0.3 
mM NaN3. Incubation was conducted in 200 L of this 
solution  containing  105  cells,  250  nCi  (9.25  KBq)  of 
[64Cu]T140-2D and 0-1000 nM of unlabeled T140-2D 
for  45  min  on  a  shaker  at  room  temperature.  After 
incubation, cells were spun through 10% sucrose us-
ing  a  desktop  Eppendorf  centrifuge  at  14,000  rpm. 
Cell  bound  radioactivity  was  measured  using  a 
gamma  counter.  Binding  results  were  expressed  as 
percent of total counts, and IC50 values were calcu-
lated using Prism software (GraphPad, La Jolla, CA). 
Cell Uptake, Internalization and Efflux Studies 
For cell uptake studies, CHO-CXCR4 cells were 
seeded into a 24-well plate at a density of 105 cells per 
well and incubated with 25 µCi/well (925 kBq/well) 
of [64Cu]T140-2D at 37°C for 5, 15, 30, 60, 120 and 240 
min. Tumor cells were then washed twice with cold 
PBS and harvested by addition of 250 µL of 0.1 mol/L 
NaOH. Internalization studies were preformed simi-
larly to the procedure describe above. After 5, 15, 30, 
60, 120 and 240 min incubation of CHO-CXCR4 cells 
with  [64Cu]T140-2D  at  37°C,  the  cells  were  washed 
twice with cold PBS and then incubated for 1 min with 
acid-washing-buffer (50 mmol/L glycine, 0.1 mol/L 
NaCl, pH = 2.8) to remove surface bound radioactive 
ligand. Thereafter, the cells were washed twice with 
cold PBS and harvested by addition of 250 µL of 0.1 
mol/L  NaOH.  For  efflux  studies,  25  µCi/well  of 
[64Cu]T140-2D  (925  kBq/well)  were  added  to 
CHO-CXCR4 cells in a 24-well plate and incubated for 
2 h at 37°C. Then cells were washed twice with cold 
PBS, and incubated with F-12K medium for 5, 15, 30, 
60, 120 and 240 min. After washing twice with PBS, 
cells  were  harvested  by  addition  of  250  µL  of  0.1 
mol/L  NaOH.  The  cell  suspensions  were  collected 
and measured in a gamma counter. Each data point is 
an average of triplicate wells. 
Binding Assay of Human and Mouse Red Blood 
Cells (RBCs) 
Mice were euthanized and blood was collected 
using  heparin  (Abbott  laboratories,  Chicago,  IL). 
Mouse  RBCs  (mRBCs)  were  separated  by  a  His-
topaque (Sigma-Aldrich) gradient, collected from the 
bottom  and  washed  three  times  with  cold  saline 
(Quality Biological, Gaithersburg, MD). Human RBCs 
(hRBCs)  were  acquired  from  the  NIH  blood  bank 
(NIH, Bethesda, MD). 
mRBCs and hRBCs were incubated in 200 µL of 
saline containing 2 x 105 cells, 250 nCi (9.25 KBq) of 
[64Cu]T140-2D and 0-1000 nM of unlabeled T140-2D 
for  45  min  on  a  shaker  at  room  temperature.  After 
incubation, cells were washed three times with cold 
saline. Thereafter, the plates were heated to 40°C and 
dried. The dried filter membranes were punched off 
from  the  wells  and  each  collected  in  a  polystyrene 
culture test tube (12 x 75 mm). Cell bound radioactiv-
ity was measured using a gamma counter. The IC50 
values were calculated by nonlinear regression anal-
ysis using the GraphPad Prism computer-fitting pro-
gram.  Each  data  point  is  a  result  of  the  average  of 
triplicate wells. 
Animals 
C57BL/6 and athymic nude mice at age of 4-6 
weeks  were purchased from Taconic (Germantown, 
NY) and housed under specific-pathogen free condi-
tions. All animal studies were conducted in accord-
ance with the principles and procedures outlined in 
the National Institutes of Health Guide for the Care 
and Use of Animals using protocols approved by the 
NIH Institutional Animal Care and Use Committee. 
Duffy  antigen/receptor  for  chemokines  (DARC) 
knockout  (KO)  mice  were  kindly  provided  by  Drs. Theranostics 2011, 1 
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Philip Murphy and Eric Schneider (NIAID, NIH, Be-
thesda, MD). 
Athymic  nude  mice  were  injected  subcutane-
ously  (s.c.)  at  two  sites  on  the  shoulder  with  107 
CXCR4-positive or CXCR4-negative CHO tumor cells 
per site. The tumors were allowed to develop for 2 
weeks prior to imaging or biodistribution studies. For 
metastatic tumor model, mice were injected intrave-
nously  via  the  tail  vein  with  106  CHO-CXCR4  cells 
and underwent imaging studies 2 weeks later. 
Biodistribution 
Fifty µCi (1.85 MBq) of [64Cu]T140-2D in a vol-
ume of 100 µL saline were injected through the tail 
veins of tumor-bearing mice. For a blocking experi-
ment, 2, 5, 10 or 400 µg of unlabeled T140-2D were 
co-injected with the labeled peptide. At 4 h postinjec-
tion, blood was drawn from the heart under anesthe-
sia and the mice were then sacrificed. Spleen, liver, 
muscle, kidneys, intestine, bone marrow, and tumors 
were removed. Bone marrow was flushed from within 
the bones, and the remaining organs were weighed. 
All  organs  were  assayed  for  radioactivity  using  a 
gamma counter. The results were calculated as per-
cent  injected  dose  per  gram  tissue  (%ID/g).  Each 
group contained 4–5 mice. 
PET Studies 
Tumor-bearing  mice  were  anesthetized  using 
isoflurane/O2 (1.5–2% v/v) and injected with 100 µCi 
(3.7 MBq) of [64Cu]T140-2D in a volume of 100 µL sa-
line.  PET  scans  were  performed  using  an  Inveon 
scanner (Siemens Medical Solutions) at 1, 2, 4 and 24 h 
post-injection.  For  blocking  experiments  relating  to 
red  blood  cells  (RBC),  100  µCi  (3.7  MBq)  of 
[64Cu]T140-2D were co-injected with 5 µg of unlabeled 
T140-2D.  
The  images  were  reconstructed  by  a 
three-dimensional ordered subsets expectation max-
imization  (3D-OSEM)  algorithm,  and  no  correction 
was applied for attenuation or scatter. Image analysis 
was done using ASI Pro VMTM software. The %ID/g 
for  the  various  tissues  was  determined  by  drawing 
regions of interest (ROIs) surrounding an entire organ 
on the coronal images. The radioactivity contained in 
the ROI divided by the dose administered to the an-
imal gave the %ID and the volume of the ROI was 
converted  to  mass,  assuming  a  density  of  1  for  all 
tissues. Each group contained 4–5 mice. 
Statistical Analysis 
Results  were  expressed  as  mean  and  SD. 
Two-tailed paired and unpaired Student’s t tests were 
used to determine differences within groups and be-
tween groups, respectively. P values <0.05 were con-
sidered statistically significant. 
Results 
Chemistry and Radiochemistry 
Conjugation  of  an  excess  of  DOTA  with  T140 
peptide  yielded  two  molecules  of  DOTA  per  T140 
peptide, one on each free lysine residue of the peptide 
(Fig. 1). The conjugated peptide was achieved in high 
chemical yield of 80-86% after HPLC purification, and 
was  analyzed  by  both  analytical  HPLC  and  mass 
spectroscopy to confirm the identity of the product. 
64Cu  complexation  into  the  desired  T140-2D 
peptide  was  very  efficient.  Following  incubation  at 
40°C for 20 min, almost no free 64Cu was detected by 
radio-TLC. The overall radiochemical yield was 86 ± 
3% (not decay-corrected, n = 6), calculated from the 
start of synthesis to the reformulation of the labeled 
peptide with saline. [64Cu]T140-2D was achieved with 
a total radiosynthesis time of 50 min, a specific activ-
ity of 0.28 - 0.30 mCi/µg (10.36 – 11.1 MBq/µg) and a 
radiochemical purity greater than 99%. 
Migration Properties of T140-2D 
In  order  to  verify  that  the  CXCR4  inhibitory 
characteristics of T140 were not affected by the addi-
tion of two DOTA molecules, we evaluated the ability 
of T140-2D to inhibit migration of Jurkat cells towards 
CXCL12.  Jurkat  T-cells  are  known  to  express  high 
levels of CXCR4 [28]. The migration experiment was 
performed using 5 µm pore membrane in a standard 
assay format. We used CXCL12 in the lower wells at 
100  ng/mL,  the  lowest  concentration  that  induces 
maximal  migration  [28], and tested various concen-
trations of T140-2D and T140 in the upper wells. Both 
T140-2D and T140 were found to inhibit Jurkat mi-
gration to CXCL12 in a similar manner. In concentra-
tions of 10 and 100 nM, there was almost no migration 
of cells with either peptide (Fig. 2A), which indicated 
that  T140-2D  retained  the  ability  to  inhibit 
CXCL12-induced chemotaxis through CXCR4. 
Homologous Displacement Binding Assay 
 The affinity of T140-2D to CHO cells transfected 
with human CXCR4 was evaluated in a homologous 
displacement  competitive  binding  assay  using 
[64Cu]T140-2D.  The  IC50  of  T140-2D  binding  to 
CHO-CXCR4  cells  was  found  to  be  2.47  ±  0.08  nM 
(Fig. 2B), which was similar to the reported  IC50 of 
T140 (2.5 nM) that was determined in a competitive 
binding assay with  125I-CXCL12 [27]. This result im-
plied that introduction of two DOTA molecules into 
the  peptide  did  not  change  its  binding  affinity  to 
CXCR4.  Theranostics 2011, 1 
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Figure 2. (A) Inhibition of SDF-1 induced migration of Jurkat cells by T140 and T140-2D. (B) Homologous displacement 
binding assay of T140-2D with [
64Cu]T140-2D using CHO-CXCR4 cells. (C) Cell uptake and internalization assays of 
[
64Cu]T140-2D in CHO-CXCR4 cells. (D) Cell efflux assay of [
64Cu]T140-2D in CHO-CXCR4 cells. (E) Homologous 
displacement binding assay of T140-2D with [
64Cu]T140-2D using mouse and human red blood cells (RBCs).  
 
 
 
Uptake, Internalization and Efflux Studies 
 The  cell  uptake,  internalization  and  efflux  of 
[64Cu]T140-2D were evaluated in CHO-CXCR4 cells. 
[64Cu]T140-2D uptake increased between 5 min to 2 h 
(Fig. 2C), reached its peak at 2 h (average of 32.76 ± 
0.57 % of total) and then slightly decreased at 4 h (av-
erage of 28.38 ± 0.63 % of total, Fig. 2C). In order to 
evaluate the internalization of the tracer, cells  were 
treated with acid buffer (pH 2.8) before the final wash. 
Approximately 1/3-1/2 of the observed uptake at all 
time  points  was  due  to  the  internalization  of 
[64Cu]T140-2D into the cells. The internalization did 
not reach a full plateau. At 2 h, an average of 11.65 ± 
0.99 % of the total peptide was internalized, which 
was a third of the uptake that was observed (Fig. 2C). 
At 4 h, there was a slight increase in the internalized 
peptide (average of 14.61 ± 0.54 % of total), which was 
about half of the uptake that was observed at this time 
point (Fig. 2C). Retention studies showed slow release 
of [64Cu]T140-2D by CHO-CXCR4, which reached a 
plateau after 1 h (Fig. 2D), suggesting that the radio-
activity was retained within the cells. 
Binding Assays to Mouse RBCs (mRBCs) and 
Human RBCs (hRBCs) 
 We have previously reported that 18F-T140 binds 
in vivo to red blood cells (RBCs) [27]. To test whether 
the addition of two DOTA molecules had any effect 
on this unwanted binding to RBCs, we evaluated the 
binding  of  [64Cu]T140-2D  to  mRBCs.  Since  the 
[64Cu]T140-2D tracer was being developed for human 
imaging, binding of [64Cu]T140-2D was also evaluated 
using  hRBCs.  Both  types  of  RBCs  bound 
[64Cu]T140-2D with similar IC50 values of 68.4 and 55.8 
nM  for  mRBCs  and  hRBCs,  respectively  (Fig.  2E), 
which  was  more  than  20-fold  higher  than  the  IC50 
value for binding to human CXCR4 (Fig. 2B).  
Biodistribution  
CHO cells and CHO-CXCR4 cells were evaluat-
ed for CXCR4 expression  by flow cytometry before 
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injection.  In  vivo,  >98%  of  the  CHO-CXCR4  tumor 
cells retained CXCR4 expression levels similar to the 
levels before injection (data not shown). Biodistribu-
tion of [64Cu]T140-2D was analyzed by organ dissec-
tion,  followed  by  gamma  counting,  in  female  nude 
mice that had been inoculated subcutaneously with 
CHO-CXCR4 and CHO tumors. Data were obtained 
at 4 h postinjection. To determine the minimal amount 
of unlabeled peptide needed to block binding to RBCs 
and  to  achieve  the  highest  tumor-to-blood  and  tu-
mor-to-muscle ratios, we preformed the biodistribu-
tion experiment with different amounts of unlabeled 
T140-2D (0, 2, 5, 10 and 400 µg, Fig. 3). 
As  expected,  when  no  unlabeled  mass  was 
added,  [64Cu]T140-2D  bound  to  RBCs  (12.73  ±  0.23 
%ID/g). [64Cu]T140-2D had relatively high uptake in 
CXCR4-expressing organs, such as spleen (16.15 ± 1.69 
%ID/g) and bone marrow (9.45 ± 1.53 %ID/g, Fig. 3) 
[31-32]  and  high  accumulation  in  metabolic  organs, 
such as liver (16.34 ± 1.40 %ID/g), intestine (3.36 ± 
0.31  %ID/g),  and  kidneys  (40.40  ±  7.25  %ID/g). 
[64Cu]T140-2D  showed  slightly  higher  uptake,  but 
was  not  statistically  significant,  in  CHO-CXCR4  tu-
mors  (3.18  ±  0.51  %ID/g)  than  in  CXCR4  negative 
CHO tumors (2.01 ± 0.37 %ID/g, Fig. 3).  
When  only  2  µg  of  unlabeled  T140-2D  were 
added,  the  binding  of  [64Cu]T140-2D  to  RBCs  was 
significantly decreased, with a more than 90% reduc-
tion of radioactivity in the blood, to a value of 1.11 ± 
0.01  %ID/g.  Due  to  the  blocking  of  [64Cu]T140-2D 
binding  to  RBCs,  the  uptake  of  [64Cu]T140-2D  was 
also significantly decreased in the CHO negative tu-
mor (1.51 ± 0.03 %ID/g, p < 0.001) and increased in 
the CHO-CXCR4 positive tumor (3.87 ± 0.42 %ID/g, p 
< 0.01, Fig. 3). [64Cu]T140-2D uptake was also slightly 
decreased in the spleen and bone marrow to values of 
12.29 ± 0.24 %ID/g and 8.16 ± 0.76 %ID/g, respec-
tively.  The  uptake  in  the  intestine  was  also  signifi-
cantly decreased (1.86 ± 0.17 %ID/g, p < 0.01), proba-
bly due to the blocking of uptake in the blood. The 
uptake  of  [64Cu]T140-2D  in  liver  and  kidneys  was 
increased  to  27.42  ±  2.68  %ID/g  and  57.03  ±  6.42 
%ID/g, respectively.  
Co-injection of [64Cu]T140-2D with 5 or 10 µg of 
unlabeled T140-2D gave patterns to the addition of 2 
µg (Fig. 3). The uptake in the blood was decreased to 
approximately  0.85  %ID/g.  The  uptake  in  the  liver 
and kidneys was also decreased. Addition of 10 µg 
blocked some of the uptake in the bone marrow as 
well (Fig. 3). The highest uptake in the CHO-CXCR4 
tumor  (4.12  ±  1.02  %ID/g)  was  achieved  with 
co-injection of [64Cu]T140-2D and 5 µg of unlabeled 
T140-2D  (Fig.  3).  Co-injection  of  [64Cu]T140-2D  and 
400  µg  of  unlabeled  T140-2D  further  decreased  the 
uptake in the blood to 0.50 ± 0.10 %ID/g. In addition, 
administration  of  400  µg  of  unlabeled  T140-2D 
blocked  the  accumulation  in  CXCR4-expressing  or-
gans, such as spleen (decreased to 3.36 ± 0.25 %ID/g), 
bone marrow (decreased to 4.31 ± 0.28 %ID/g) and 
CHO-CXCR4 positive tumor (decreased to 1.91 ± 0.25 
%ID/g). These results suggested a specific binding of 
this peptide to CXCR4 (Fig. 3). 
 
 
 
 
 
 
Figure 3. Biodistribution of [
64Cu]T140-2D in female athymic nude mice bearing CHO and CHO-CXCR4 tumors at 4 h 
post-injection of the labeled peptide in the presence of different amounts of unlabeled peptide (0, 2, 5, 10 and 400 µg). 
Results shown are averages of 4-5 mice ± SD. *P < 0.01 vs. [
64Cu]T140-2D alone.  
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Blocking the uptake in the RBCs by adding dif-
ferent amounts of unlabeled T140-2D (2, 5, 10 and 400 
µg) significantly increased the tumor-to-blood ratios 
in  comparison  to  the  result  achieved  without  cold 
mass (Table 1). Co-injection of 5 µg T140-2D gave the 
highest  tumor-to-blood  and  tumor-to-muscle  ratios 
(4.86 ± 0.89 and 12.56 ± 3.66, respectively).  
 
Table 1. CHO-CXCR4 tumor-to-muscle and tu-
mor-to-blood ratios at 4 h postinjection of 
64Cu-T140-2D in 
the presence of different amounts of T140-2D (n = 4 or 5 
mice per group).  
  Tumor-to-blood  Tumor-to-muscle 
64Cu-T140-2D  0.25 ± 0.01  3.75 ± 0.50 
64Cu-T140-2D + 2 µg 
T140-2D 
3.46 ± 0.32   10.41 ± 1.15 
64Cu-T140-2D + 5 µg 
T140-2D 
4.86 ± 0.89  12.56 ± 3.66 
64Cu-T140-2D + 10 µg 
T140-2D 
4.19 ± 0.11   5.37 ± 0.51 
64Cu-T140-2D + 400 µg 
T140-2D 
3.77 ± 0.46   7.60 ± 0.62 
 
 
 
To  test  whether  the  usage  of  different  metals, 
such  as  Ga-68,  for  complexation  with  the  DOTA 
would  provide  better  in vivo  kinetics,  these  experi-
ments were repeated using [68Ga]T140-2D. However, 
the  results  obtained  were  similar  to  those  of 
[64Cu]T140-2D with the liver and kidneys displaying 
high uptake (Supplemental Fig. 1). 
MicroPET Imaging Studies 
The  tumor-targeting  efficacy  of  [64Cu]T140-2D 
was evaluated by static microPET scans using mice 
bearing subcutaneous CHO-CXCR4 and CHO tumors 
(Fig.  4)  and  mice  injected  intravenously  with 
CHO-CXCR4 cells (Fig. 5). The %ID/g was calculated 
from PET images for the blood, muscle, liver, kidneys, 
CHO-CXCR4 tumor and CHO negative tumor at dif-
ferent time points (Fig. 4).  
Mice that were injected with [64Cu]T140-2D had 
high uptake in the blood and the abdominal region 
(Fig. 4A&B). This high uptake in the blood remained 
stable over time, to give high background throughout 
the image and specifically in the heart, liver and kid-
neys, masking some of the uptake in the tumors.  
 
 
 
Figure 4. Representative coronal PET images of an athymic nude mouse bearing CHO-CXCR4 (right shoulder) and CHO 
(left shoulder) after injection with 100 µCi of [
64Cu]T140-2D without (A) and with (C) 5 g of unlabeled peptide (low 
specific activity tracer). Arrows indicate tumors. Uptake of [
64Cu]T140-2D without (B) and with (D) 5 g of unlabeled 
peptide in tumor-bearing mice over time. Results were calculated from PET scans and are shown as averages of 4-5 mice ± 
SD.  
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Since  the  biodistribution  results  demonstrated 
that  the  highest  tumor-to-background  ratio  and  the 
highest tumor uptake were achieved by the addition 
of 5 µg of unlabeled T140-2D, the mice used for mi-
cro-PET studies were co-injected with [64Cu]T140-2D 
and  5  µg  of  unlabeled  T140-2D.  At  all  time  points, 
CXCR4-positive,  but  not  CXCR4-negative  tumors, 
were  clearly  visualized  (Fig.  4C).  The  uptake  in 
CHO-CXCR4  tumor  was  steady  over  time  (Figs. 
4C&D). High uptake was also seen in the liver and 
kidneys,  but  decreased  at  24  h  post-injection  (Figs. 
4C&D). 
In  order  to  evaluate  whether  [64Cu]T140-2D  is 
suitable  for  imaging  tumors  at  internal  sites,  mice 
were injected intravenously with CHO-CXCR4 cells. 
PET  scanning  detected  CHO-CXCR4  tumors  in  the 
chest and spine (Fig. 5) at 2 h and 24 h postinjection of 
the  tracer.  Accumulation  of  [64Cu]T140-2D  was  ap-
proximately 2.5 %ID/g in the small tumor lesions in 
the chest and 4 %ID/g in the lesion on the spine (Fig. 
5) and was stable for 24 h.  
 
 
 
 
Figure  5. Representative PET images of mouse bearing 
internal  tumors  at  2  and  24  h  post-injection  of 
[
64Cu]T140-2D with 5 g of T140-2D. Left – coronal ventral 
slices, Middle – coronal dorsal slices, Right – sagittal view. 
Arrows indicate CHO-CXCR4 tumors. 
 
 
RBCs were previously reported to express sev-
eral  scavenger  receptors,  including  one  chemokine 
scavenger  receptor--the  Duffy  antigen  receptor  of 
chemokine (DARC) [33]. The fact that T140 binds to 
CXCR4 highlighted DARC as a possible receptor that 
binds  T140.  To  test  whether  T140  peptide  binds  to 
DARC,  DARC  knockout  mice  were  injected  with 
[64Cu]T140-2D and scanned by microPET side by side 
with the wild-type mice. However, similar uptake of 
[64Cu]T140-2D was observed in the blood of both mice 
strains (Fig. 6), eliminating the possibility of DARC as 
a candidate for [64Cu]T140-2D binding on RBCs. The 
high uptake in the blood of DARC knockout mice was 
confirmed by biodistribution (data not shown). 
 
 
 
 
Figure 6. Representative coronal PET images of wild-type 
(WT) C57BL/6 mice (Left) and Duffy antigen/receptor for 
chemokines (DARC) knockout (KO) mice (Right) at 2 h 
after injection with 100 µCi of [
64Cu]T140-2D. 
 
Discussion 
T140  peptide  binds  CXCR4  with  high  affinity 
and high inhibition potency. It was shown to increase 
in vivo mobilization of stem cells from the bone mar-
row  more  than  the  approved  drug  Mozobil 
(Plerixafor/AMD3100)  [34]. Moreover, it was found 
to reduce the growth of human acute myeloid leuke-
mia and multiple myeloma xenografts in mice, and to 
directly induce apoptosis of malignant cells [35]. 
We  have  recently  reported  on  the  labeling  of 
T140 with fluorine-18 and its evaluation in-vivo as an 
imaging  agent  [27].  We  have  shown  that  when  in-
jected  in  high  specific  activity  (with  no  addition  of 
unlabeled mass of peptide), [18F]T140 bound to mouse 
RBCs and gave high background [27]. We were able to 
block the binding to RBCs by co-injection of the tracer 
with  unlabeled  mass  of  T140  peptide  (low  specific 
activity tracer), resulting in elevated accumulation in 
CXCR4 positive tumor, but not CXCR4 negative tu-
0%ID/g
4%ID/g 2 h
24 hTheranostics 2011, 1 
 
http://www.thno.org 
260 
mor,  and  high  tumor-to-background  ratios  [27]. 
However, radiosynthesis of 18F-T140 requires several 
steps, a long reaction time, and results in low yield, 
limiting its potential for clinical use. 
In this paper we tried to address this problem 
and  simplify  the  radiosynthesis  by  introduction  of 
two DOTA molecules, one on each of the free lysine 
residues of T140, for labeling with PET metal isotopes, 
such  as  copper-64,  to  give  a  new  T140  derivative, 
[64Cu]T140-2D  (Fig.  1).  Complexation  of  copper-64 
into  the  peptide  was  very  efficient  and  straightfor-
ward, resulting in an overall short reaction time, high 
yield and no need of semi-preparative HPLC purifi-
cation. Labeling with copper-64 also allowed scanning 
the mice for longer time periods. PET scans with low 
specific  activity  tracer  gave  a  clear  visualization  of 
CXCR4-positive tumor, but not CXCR4 negative tu-
mor (Fig. 4C) and enabled imaging of small internal 
lesions of CXCR4-expressing tumors in the chest and 
spine (Fig. 5). 
Introduction  of  two  DOTA  into  T140  did  not 
change its high binding affinity to CXCR4 or its high 
inhibition  potency  (Fig.  2A&B),  in  accordance  with 
the results reported by Hanaoka and Tamamura et al. 
that  Arg2,  NaI3,  Tyr5  and  Arg14  are  the  amino  acid 
residues  indispensable  for  the  antagonistic  activity 
[24, 36]. We also found that approximately half of the 
bound tracer was internalized into the cells and re-
tained within the cells over time (Fig. 2C&D). 
[64Cu]T140-2D  showed  similar  behavior  as 
[18F]T140  in  terms  of  binding  to  mouse  RBCs  and 
human RBCs (Fig.  2E). This can be problematic for 
clinical applications, in terms of quantification of the 
receptor levels in vivo. Similar to the circumstance for 
[18F]T140, binding of [64Cu]T140-2D to RBCs can be 
blocked  by  addition  of  unlabeled  peptide.  We  hy-
pothesize that injection of the peptide i.v. primarily 
interact with RBCs because this is the first binding site 
the  peptide  encounters  in  the  circulation.  Once  the 
binding  sites  on  RBCs  are  blocked,  the  remaining 
peptide can bind to CXCR4. 
Co-injection  of  [64Cu]T140-2D  with  5  µg  of 
T140-2D  gave  the  highest  tumor-to-blood  and  tu-
mor-to muscle ratios (4.86 ± 0.89 and 12.56 ± 3.66 re-
spectively,  Table  1).  When  different  masses  of 
T140-2D were added, the uptake of [64Cu]T140-2D in 
the blood was significantly decreased, however it was 
much higher than that achieved with [18F]T140 and 10 
µg  of  T140  [27].  For  example,  in  a  co-injection  of 
[64Cu]T140-2D and 10 µg of T140-2D, the uptake in the 
blood  was  0.86  ±  0.09  %ID/g,  while  co-injection  of 
[18F]T140 and 10 µg of T140 gave a value of 0.12 ± 0.04 
%, which was 7 times lower than the [64Cu]T140-2D 
blood value. Blocking experiments by co-injection of 
[64Cu]T140-2D  and  400  µg  of  T140-2D  still  gave  a 
higher value (0.50 ± 0.1%ID/g). Overall, the accumu-
lation  of  low  specific  activity  [64Cu]T140-2D  in  the 
blood resulted in tumor-to-blood ratios that were al-
ways  lower  than  the  ratios  achieved  with  the  fluo-
rine-18 derivative. 
RBCs do not express CXCR4, however they ex-
press scavenger receptors such as Duffy antigen re-
ceptor of chemokine (DARC), which is able to bind to 
various chemokines [33] and seems to be a reasonable 
candidate  to  bind  T140.  However,  no  difference  of 
[64Cu]T140-2D  in  blood  uptake  was  found  between 
the DARC knockout mice and wild-type mice (Fig. 6), 
eliminating  DARC  as  a  candidate  for  binding 
64Cu-T140-2D.  Hence,  the  binding  site  for  T140  on 
RBC is yet to be found. 
One downside of [64Cu]T140-2D imaging, when 
compared to [18F]T140, is the significantly higher up-
take in the liver and kidneys that remained high over 
time  (Fig.  4).  Labeling  T140-2D  with  another  PET 
metal isotope,  68Ga, gave similar results with persis-
tent  activity  accumulation  in  the  liver  and  kidneys 
(Supplemental Fig. 1). The uptake in the metabolic 
organs  was  likely  a  result  of  transchelation  of  the 
metal ion from the DOTA chelator [37].  
CONCLUSIONS 
Tumor CXCR4 expression can be imaged using 
[64Cu]T140-2D  but  with  high  uptakes  in  the  blood 
and metabolic organs. The addition of unlabeled pep-
tide, viz, low specific activity tracer, significantly re-
duced  the  red  blood  cell  binding  without  compro-
mising tumor uptake leading to clear tumor contrast. 
The high  liver and  kidney uptake of [64Cu]T140-2D 
may  be  reduced  by  using  chelators  that  form  com-
plexes  with  64Cu  that  are  theramodynamically  and 
kinetically more inert complexes with 64Cu.  
SUPPLEMENTARY MATERIAL 
Supplementary Figure 1 
http://www.thno.org/v01p0251s1.pdf 
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